Last update Aug. 18, 2017
It promotes pancreatic insulin secretion by inhibiting the DPP-4 enzyme that degrades the intestinal hormone GLP-1 that is activated when eating (Baetta 2011, Scheen 2011).
Oral administration, once daily.
Very low risk of hypoglycemia. Doses 6 times higher than normal for 10 days or 4 times higher for 28 days do not produce side effects (EMA 2016). The most common side effect is rhinopharyngitis.
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (EMA 2016, Scheen 2011): large volume of distribution, moderately high molecular weight and low liposolubility, make it unlikely that it will pass through to breast milk in significant amounts.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Diet, exercise, and breastfeeding improve blood sugar levels.
Among the antidiabetics of this same group, Saxagliptin and Vildagliptin would be preferable due to their short half-life (less than 3 hours).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM